2.37
-0.12(-4.82%)
Currency In USD
| Previous Close | 2.49 |
| Open | 2.52 |
| Day High | 2.55 |
| Day Low | 2.36 |
| 52-Week High | 3.31 |
| 52-Week Low | 1.05 |
| Volume | 2.59M |
| Average Volume | 3.88M |
| Market Cap | 619.83M |
| PE | -6.97 |
| EPS | -0.34 |
| Moving Average 50 Days | 2.31 |
| Moving Average 200 Days | 1.98 |
| Change | -0.12 |
If you invested $1000 in Taysha Gene Therapies, Inc. (TSHA) since IPO date, it would be worth $98.5 as of June 25, 2025 at a share price of $2.37. Whereas If you bought $1000 worth of Taysha Gene Therapies, Inc. (TSHA) shares 3 years ago, it would be worth $592.5 as of June 25, 2025 at a share price of $2.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
GlobeNewswire Inc.
Jun 03, 2025 9:17 PM GMT
Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones supporting
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
May 29, 2025 2:40 AM GMT
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
May 28, 2025 8:02 PM GMT
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases